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Abstract The advances in science have resulted in the
emergence of nanotechnology, which deals with the design
and use of tools and devices of size 1–100 nm. The
application of nanotechnologies to medicine is thus termed
nanomedicine. Significant research has been focused on
this new and exciting field and this review article will
describe the basics of nanomedicine. This is followed by its
experimental and clinical applications in diagnostics, drug
therapy and regenerative medicine. Safety issues of in vivo
use of nanomaterials are also discussed. In the future, it is
foreseen that nanomedicine will facilitate the development
of personalized medicine and will have a major impact on
the delivery of better healthcare.
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Introduction
Nanotechnology is defined as the design, characterization
and application of structures, devices and systems by
controlling shape and size at nanometer scale level (rang-
ing from 1 to 100 nm) [1]. A nanometer is one billionth of
a meter (10-9 m). Putting this into biological context, the
width of DNA is approximately 2.5 nm and protein mol-
ecules measure 1–20 nm. This new technology has already
been widely used in microelectronics, materials manufac-
ture, robotics, and dye processing.
When larger micro/macro conventional materials are
engineered into nanosized particles and materials, com-
pletely different physiochemical and biological properties
are seen (Fig. 1) [2, 3]. Furthermore, as many molecules
involved in biological events interact fundamentally at the
‘‘nano’’ level, nanomaterials engineered are thus believed
to be able to modulate or change the biological processes at
the cellular level [4, 5].
In recent years, nanotechnology has extended into the
field of medicine and this new discipline has been termed
‘‘Nanomedicine’’. In contrast to conventional therapies
where the basic approach is to remove diseased cells
faster than healthy cells, nanomedicine attempts to use
sophisticated approaches to either kill specific cells or
repair them, one cell at a time. With rapid development of
nanomedicine, sub-branches in nanooncology [6–8],
nanoneurology [9–12], nanocardiology [13–15], nanoor-
thopedics [16–19], as well as nanoophthalmology [20]
have also emerged. In terms of clinical applications,
nanomedicine is providing a new and promising prospect
for diagnosis and therapy. For instance, some nanomate-
rials have the potential to modulate and reduce the
immune response to foreign tissues such as breast
implants, which will contribute better outcomes like faster
healing, better cosmetics, as well as less foreign body
response [21]. Furthermore, nanotechnology has also been
incorporated in the field of tissue engineering and
reconstruction, which will greatly enhance and contribute
to the field of regenerative medicine [22]. Nanomedicine
thus offers new possibilities towards the development of
personalized medicine, so as to allow improved treatment
efficacies for many diseases.
In this review, we will describe relevant research and
clinical application of nanotechnology and nanomaterials
in clinical diagnosis and therapy.
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Nanomedicine in diagnosis
Early diagnosis plays an important role for the successful
prevention and efficient treatment of diseases. This is
particularly true in the case of cancer, as earlier diagnosis
correlates with a significant increase in the cure rate. Fur-
thermore, more information about the molecular mecha-
nisms of the pathophysiology will lead to the development
of newer and better anticancer drugs. The advantage of
nanoparticle-based diagnostics lies in their higher sensi-
tivity and selectivity when compared to classical methods.
MRI contrast
Magnetic resonance imaging (MRI) is an important diag-
nostic imaging tool in the management of cancer. The
addition of contrast agents like gadolinium in MRI helps to
enhance image quality. Nanoparticles present a new col-
lection of contrast agents. For example, gadolinium-based
dendrimers is an enhancement of the traditional gadolin-
ium, and can be effective at a very low concentration.
A number of different dendrimers can target different
organs. Furthermore, iron oxide nanoparticles can generate
superior signal and have been used in liver imaging and for
cell tracking studies. As they are metabolized through
endogenous iron salvage pathways, they have already been
introduced as clinical contrast agents.
Some nanodelivery devices implanted in body, not only
contributes to carry and release of therapeutic drugs mol-
ecules, but also can be used for in vivo imaging. Mean-
while, the self-assembling characteristics of nanodelivery
devices in body, on one hand, could serve as a delivery
system for improvement of therapeutic efficacy [23]. On
the other hand, their location in body can be tracked and
imaged easily and clearly by MRI due to metallic nature in
some of nanodelivery devices. Furthermore, these con-
tainers can be inserted directly at the site of an injury or
tumor tissue, which would act as biosensors within the
body to clearly demonstrate illness change via signaling
frequency, while this differential signaling frequency will
be easily detected by MRI contrast. John et al. [24, 25]
reported the application of magnetic nanoparticles with
magnetomotive optical coherence tomography for imaging
of mammary tumors in rats. They claimed dynamic
magnetomotive imaging is capable of detecting very low
concentrations of nanoparticles with low-intensity mag-
netic fields, which would present a clinical possibility to
use MRI to identify tumor location followed by magneto-
motive optical coherence tomography-guided biopsy or
surgery [26]. So far some nanomaterials with better
biocompatibility have been also used for imaging diagno-
sis, including iron oxide, manganese oxide, and composite
nanomaterial. These nanometal materials are widely stud-
ied as carriers for delivery of anti-cancer drug; meanwhile,
they are revealed as the important candidates in nanodi-
agnostic imaging materials, as they are biocompatible and
have superior contrast effects in MRI assay [27–29].
Fluorescent nanoparticles for surgery
In the past decades, resection of the tumor has been guided
by pre-operative imaging and also surgeons’ ability to
differentiate tumor from normal tissues during operative
procedures. Ensuring an adequate margin during tumor
excision and minimizing the destruction of excessive nor-
mal tissue is thus a great challenge. This is particularly true
in brain tumor surgery, as it is widely known that accurate
tumor delineation will help improve survival rate and
quality of life after surgery. Staining of tumor tissue using
fluorophores or visible dyes, such as fluorescein, indocya-
nine green, bromophenol blue, and Coomassie Blue
[30–33] has been attempted in brain tumor surgery. Many
limitations still exist, including requirement to special
lighting and fast diminishing of fluorophores/dyes (short-
lasting retention), as well as poor visual contrast or target
specificity.
The new physiochemical and biomedical characteristics
of nanomaterials have made it possible for fluorescent
nanoparticles to solve these limitations or obstacles.
Fluorescent nanoparticles have several advantages,
including selective tumor targeting, tumor-specific target-
ing moiety, high loading and quality of contrast agents,
non-toxic [34, 35]. In this regard, Veiseh et al. [36] con-
jugated iron oxide-based nanoparticles with near-infrared
fluorescent dye Cy5.5 to form fluorescent nanoparticles as
a new dye, and proposed that they could inhibit brain tumor
cell proliferation and invasion36, afterwards, they further
revealed this fluorescent nanoparticles could pass through
Fig. 1 Schematic diagram to demonstrate the effect of smaller
particle size on the surface area to volume ratio. Once subject was
manufactured into smaller ones, the total surface area will be
significant larger than original one. Therefore, the ratio of surface to
volume will also be increased
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blood–brain barrier and reach tumor site, as well as
aggregation in local tumor tissue [37]. Furthermore, in
order to enhance biocompatibility, stability in physiologi-
cal solutions, nontoxicity, and the ability to traverse bio-
logical barriers, they again reported a polyethylene glycol
(PEG)-mediated synthesis process, aiming to produce well-
dispersed, ultrafine, and highly stable iron oxide nanopar-
ticles for in vivo applications [38]. Despite deep tissue
penetration capability of these fluorescent nanoparticles,
they were only visualized under separate monitor and
invisible to the naked eye. Orringer et al. targeted glioma to
explore visual tumor delineation by using nanoparticles
surface-conjugated F3 peptide, and they developed a
polyacrylamide (PAA) nanoparticle containing blue dye,
Coomassie Brilliant Blue G-250 (CB). There was a better
visible color contrast enhancer for intraoperative tumor
delineation, and was also safe for intravenous injection,
even at high doses [39]. Recently Nie et al. engaged in
in vivo experiment using these fluorescent nanoparticles
and further revealed this tumor-targeting deep-blue nano-
particle-based visible contrast agent was effective in
tumor-specific color staining [40].
Nanoprobes/chips array technology
Nano-scale materials are the ideal candidates to be used as
bio-probes in vitro as they are more sensitive to very small
targets. Their enlarged volume/surface ratio, surface tailor-
ability, multi-functionality and intrinsic optical properties
offer remarkable opportunities to detect and monitor slight
signal variation in complex biological environments
[41, 42]. For instance, the larger surface area of nanoma-
terials greatly enhances attachment of target-specific mol-
ecules, which contributes to ultrasensitive detection [43].
Thus, accurate diagnosis becomes possible at the molecular
or single cell level due to fast responses and improved
sensitivity. The ultimate goal of in vitro diagnostics is a
relatively non-invasive, early, and accurate detection of
biological disease markers during screening. One clinical
scenario is the accurate and rapid diagnosis of incubating
respiratory viruses in pre-operative patients in an attempt to
reduce post-operative complications. Currently, many
nanoprobe platforms have been described.
One example is quantum dots (QDs). These are well-
established nano-scale crystals composed of an inorganic
elemental core like cadmium or mercury, and a surround-
ing metal shell with resistance to photo-bleaching, spread
absorption spectra covering UV to near-infrared region,
and long fluorescence lifetimes, as well as size-dependent
optical properties. They have broad biomedical applica-
tions in cellular imaging, immunoassays, biosensors, and
microfluidic protein chip detection [44–48]. Furthermore,
the photo-physical properties of QDs enable them to
effectively link with acceptors and amplify target signal via
enhanced energy-transfer efficiency. These features allow
QD-based nanoprobes to generate a very distinct signal,
even in the case of low target abundance [49]. In the bio-
medical area, QD optical probes have been used in signal
transduction due to their better fluorescence resonance
energy transfer properties, and designed to detect the pro-
teins and peptides, as well as those small molecules
[50, 51].
Nanomedicine in therapeutics
One advantage of nanoparticles for biomedical applications
is their ability to overcome various biological barriers and to
localize into the target tissue. The nanoparticles could be a
vector/carrier or be the active drug itself. The targeting of
specific tissues could be due to passive targeting or active
localization using specific additional molecules, which
allows for molecular recognition of the target tissue or for
triggered release of the payload at the disease site. Further-
more, nano-formulations can provide sustained release pro-
files for up to 24 h, which can improve patient compliance.
Nanocarriers for cancer drug delivery
Although chemotherapy has been one of the principal
treatment modalities for cancer, efficacies are mostly
unsatisfactory due to non-specific action, which results in
significant systemic side effects [52–54]. Ideally, anti-
cancer drug molecules should act specifically on target
cancer cells and accumulate preferentially at target tissues
in sufficient concentration [55, 56]. Therefore, improve-
ment of delivery efficacy of anti-cancer drugs can enhance
the selective cytotoxicity to tumor cells, and is essential to
reducing side effects in the body.
Cancer vasculatures have unique characteristics in both
morphological structure and physiological features. These
include: (1) highly chaotic and irregular arrangement of
blood vessels in contrast to normal ones [57, 58]; (2) cancer
blood vessels has overabundance of anionic phospholipids
and proteoglycans; (3) vascular networks in cancer tissue
have increased permeability to circulating macromolecules
compared with normal ones. The size of vascular gap
openings to cancer tissue usually increases up to 400–600 nm
[59], which is remarkably larger than blood vessels in normal
tissues. Macromolecules and nanoparticle drug carriers
engineered to a specific size can thus preferentially extrava-
sate from leaky cancer vasculatures and accumulate in cancer
tissue [60–62]—enhanced permeability and retention (EPR)
effect. The EPR effect allows accumulation of anti-cancer
drugs in cancer tissues, thereby allowing for effective anti-
cancer therapy with minimal drug toxicity.
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So far a variety of nanoscale drug delivery systems have
been developed. These nanosystems include polymeric
micelles, liposomes, dendrimers, and nanoemulsions [63]
(Fig. 2). Polymeric micelles are spherical and nanoscale
colloidal carriers formed by the self-assembly of amphi-
philic copolymers with both hydrophilic and hydrophobic
segments in aqueous solution. These polymeric micelles
are effective drug carriers for cancer therapy as they can
incorporate water insoluble anti-cancer drugs in their
hydrophobic core. Kataoka et al. found that the hydrophilic
shell layer of these nano-carriers can prevent the incorpo-
rated drugs from degradation caused by enzymes and avoid
non-selective uptake by macrophages distributed in whole
body [64].
Liposomes are spherical self-closed structures consisted
of concentric lipid bilayers. They have an inner aqueous
compartment enclosed by those lipid bilayers which are
similar to biological membranes. As a result of this, the
solubility of hydrophobic chemotherapeutics is increased
and trapping of drug molecules can be achieved with high
potency. Recent study has showed incorporation of PEG
onto liposomes surface, could further enhance their in vivo
stability, furthermore, PEG-stabilized liposomes exhibited
a prolonged plasma half-life, as the surface-exposed PEG
chains form a protective layer around liposomes to reduce
clearance by macrophage in reticuloendothelial system
[65]. In a mouse neuroblastoma model, Lee et al. demon-
strated that liposome-based gold porphyrin nanoparticles
composite could inhibit tumor growth with reduction of
systematic toxicity induced by gold porphyrin [66, 67].
Dendrimers have also been demonstrated to be a good
delivery system to carry the anti-cancer agent. Klutz et al.
adopted dendrimer for gene delivery for treatment of
neuroblastoma, and found they could effectively modulate
immune response [68].
In terms of clinical application, liposomes are the most
established systems used for drug delivery. Liposomal
nanotherapeutics for cancer treatment have been on the
market for more than a decade, whereas other liposomal
drugs are in various stages of clinical development. Some
examples of available drugs are: liposomal amphotericin B,
liposomal doxorubicin, liposomal daunorubicin [69–71].
All the liposomal formulations have been shown to have
higher efficacy and lower toxicity than non-liposomal
preparations.
Naked metallic nanoparticles
Among all the naked nanodrugs, silver nanoparticles
(AgNPs) and iron oxide nanoparticles are the most widely
studied. For centuries, silver has been utilized as an
effective anti-microbial agent. With the advent of nano-
technology, silver can now be formulated into nanoparti-
cles. They seem to have all the beneficial effects of silver
compounds without associated toxicity. Indeed, many
studies showed that AgNPs could be even more effective in
bacterial killing through damaging bacterial cellular pro-
teins and blocking the microbial respiratory chain system
[1, 72–74]. Tian et al. revealed that topically applied
AgNPs reduced both local as well as systemic inflamma-
tion in a burn wound model [75]. The anti-inflammatory
action was also confirmed also in a peritoneal adhesion
model in mice [76]. The combined anti-bacterial and anti-
inflammatory actions contributed to significantly faster
wound healing. Regarding clinical applications, AgNPs has
already been using in a commercially available dressing for
burn wounds—Acticoat (Smith & Nephew) [77–80].
Other products containing nanosilver include silver-
impregnated catheters [81], and surgical mesh [82].
For the superparamagnetic iron oxide nanoparticles
(SPIONs), the main biological function is to assist delivery
of small-molecule drugs or biological agents to the target
site and limiting its exposure to healthy tissue. As SPION
are magnetic, they can also be used as a contrast agent in
Fig. 2 Schematic diagram showing various nano-delivery systems.
a Polymicelles consist of a hydrophilic shell, which improves the
biocompatibility and stability of the carrier in circulation, and a
hydrophobic core for conjugation with hydrophobic anti-cancer drug
molecules. b Liposomes have bimolecular lipid layers. The outer
hydrophilic layer allows easy passage through cell membranes. The
inner layer is hydrophobic and contains drug molecules. c Dendrimers
are repetitively branched molecules typically symmetric around the
core. Their ‘‘tree branch’’ like structure allows efficient drug carrying
capacity and the ease of attaching functional groups for targeted
delivery
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MRI for disease diagnosis and treatment monitoring. In
fact, several SPION formulations have been approved for
clinical use including dextran-coated iron oxide (Feridex)
for liver and spleen imaging, and ferumoxytol for iron
replacement therapy [83, 84]. SPIONs are safe and stable
nanodelivery system to carry genes, including small
interfering RNA (SiRNA), nucleic acids and plasmid DNA
[85–87], as well as chemotherapy and proteins [88–90].
Nanoparticles for vaccine/gene delivery
Current biological vaccines consist of polynucleotide vac-
cines, DNA vaccines, and plasmid vaccines. Some issues
including efficient delivery of the vaccines molecules to
target cell population, its localization to the nucleus of
these cells, and ensuring that the integrity of the polynu-
cleotides is maintained during delivery to the target site,
are essential to maximize the biological efficacy [91]. In
this regard, nanotechnology can serve as an efficient sus-
tained release delivery system for loaded vaccines. The
nanoparticles could release these vaccines molecules at a
sustained rate leading to continuous gene expression. This
preserves the level of vaccine molecules in blood and
maintains continuous production of specific antibody.
Nano-surgery
Advances in nanotechnology in recent years have resulted
in a new concept termed nanoscale laser surgery. Cellular
structures could be manipulated at nanoscale level using
femtosecond (fs: one millionth of a billionth of a second)
laser pulses. Femtolaser can selectively cut a single strand
in a single cell. This means that even organelles inside a
single cell could be removed without disrupting rest of cell.
Thus, it may provide an ideal tool in ophthalmological
surgery [92].
On the other hand, nano-cryosurgery provides a new
variation of an old concept. The principle of it lies in the
loading of specific nanoparticles within and around cancer
tissue. Their excellent cooling conductivity will contribute
to the fast freezing at a lower temperature (Fig. 3). Cancer
cell apoptosis induced by freezing action and curative
efficacy was improved greatly [93]. Although the obstacles
for nano-cryosurgery technology to be used in the clinic are
to be overcome, it is believed to be a promising choice for
tumor control in the future.
Nanomedicine meets regenerative medicine
This subject engages in the study of application of
nanomaterials or devices on damaged tissues or organs,
aiming to promote tissue regeneration and repair with
minimal scar and maximal function after injury. This field
encompasses a vast area but we shall focus mainly on the
aspects of skin and bone regeneration, as damages to these
organs are the most commonly encountered.
Regarding to the regeneration and repair of skin and
bone tissue using nanomaterials, intensive research work
have been carried out trying to accelerate wound healing
and recovery of mechanical function. In this regard, Liu
et al. explored the use of AgNPs on skin excisional wound
healing. The in vitro and in vivo experiments revealed
that AgNPs could promote keratinocyte proliferation in the
re-epithelization process, while they could drive the dif-
ferentiation of fibroblasts into myo-fibroblast for wound
contraction (Fig. 4) [94]. Further study demonstrated that
the mechanical function in healed skin after treatment with
AgNPs had similar elastic force, collagen deposition, as
well as collagen fibrils alignment to normal skin [95].
These indicated that AgNPs could regulate remodeling
process during skin tissue regeneration.
For bone repair, nanotechnology has contributed
towards the design and construction of scaffolds using
various materials, such as collagen, calcium sulfate,
Fig. 3 Schematic diagram showing the concept of nano-cryosurgery.
a Specific nanoparticle solution is injected around cancer tissue to
improve thermal conductivity, followed by insertion of cryo-probe
under image guidance. b Super-conductive nanoparticles lower the
freezing temperature and the freezing zone (dashed line) around
cancer tissue when compared to conventional cryosurgery
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chitosan hydroxyapatite [96–99]. These can be further
modified with the addition of nanoparticles like boron,
growth factors, and/or stem cells [100–103]. The various
nano-based scaffolds acted on bone matrix to promote
recruitment of circulating stem cells, induce proliferation
and eventual differentiation into mature osteoblasts.
Other applications of nanotechnology in regenerative
medicine include repair of nerve injuries. Liu et al. inves-
tigated the feasibility of incorporating neurotrophin-3 and
chondroitinase ABC onto electrospun collagen nanofibers
for the treatment of spinal cord injuries. Their results
showed accelerated nerve regeneration through provision of
topographical signals and multiple biochemical cues arising
from both nanofibrous scaffolds and cytokines [104].
Another approach was demonstrated by Ellis-Behnke
et al. He used self-assembling peptides to explore their
roles in axonal regeneration after injury in the central
nervous system. In an optic tract injury model, injection of
self-assembling peptide locally resulted in regeneration of
axons through the site of acute injury, with subsequent
functional return of vision [105].
The use of self-assembling nanofibrous scaffolds was
also found to be effective in modulation of stem cells in
wounds. Segers et al. showed that addition of stromal cell-
derived factor-1 (SDF-1) in self-assembling nanofibrous
scaffolds promoted stem cell recruitment and improved
cardiac function in myocardial infarction model [106].
Toxicology: should we be concerned?
With the wide use of various nanomaterials in the
biomedical field, the issue of potential toxicity is of
concern. Compared with conventional materials, nanopar-
ticles can gain easy access to cells, tissue, even organs.
Many researchers have been already engaging in cytotox-
icity evaluation in various cells, to investigate and estimate
the potential toxicity induced. Most of these studies are in
vitro toxicity studies, and the general consensus is that
nanomaterials at low dose will not cause significant cyto-
toxicity. However, just like most other agents or drugs,
increasing concentration or exposure time of nanomaterials
will result in observable cytotoxicity. Furthermore, the
toxicity thresholds for various cell types are also different.
In addition to in vitro toxicity studies, in vivo toxicity
studies need also be carried out. Oral and intravenous
injections are the main administration routes of nanoma-
terials. Compared to in vitro toxicity studies, there are
significantly fewer reports on in vivo toxicity of nanoma-
terials. Relevant clinical toxicity reports are even more
sparse. Furthermore, between the biomedical efficacy and
potential toxicity, a balance point probably exists, which
can surely be swung towards the safety side by techno-
logical advances. For example, through precise modulation
of size and shape of nanomaterials, the toxic effect can be
modified. Furthermore, with the development of tissue
engineering and scaffolds as well as nanodelivery system,
the sustained release of nanomaterials in specifically tar-
geted organs in the body can be achieved, thus reducing
systemic toxicity effect. Nonetheless, it is imperative that
for a new nanoproduct to be introduced, vigorous testings
need to be conducted to ensure safety to our patients.
Conclusion
Nanomedicine is now fully into our daily life and has
brought innovation to current diagnostic and therapeutic
approaches in clinical medicine. In the next decade, newer
materials, technologies and methods will be emerging to
promote further development of nanomedicine. Mean-
while, more research work in this field will make this
subject more mature and eventually serve as a more
effective tool for our healthcare system.
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